Analysis: Shree TNB Polymers

BSE:SHREETNB

Growth thesis

Shree TNB Polymers is a Silvassa-based polymer processor — HDPE, PP and PPH pipes and DWC pipes, solid industrial sheets and PP corrugated sheets — that has spent the last three years earning a margin recovery on a shrinking topline and has now committed to a capacity step-up funded by equity rather than debt. FY26 revenue from operations was ₹19,812.73 lakhs against ₹20,785.56 lakhs in FY24, a three-year CAGR of negative 1.59%, while EBITDA margin moved from 7.32% to 9.69% and PAT from ₹503.05 lakhs to ₹713.46 lakhs. The earnings growth therefore came almost entirely from the cost line, not from volume. That is the setup the new capital is meant to break.

The company listed on 8 October 2026 and has received IPO proceeds. What management said on the 19 November 2026 Q2 FY27 call matters more than the offer document's schedule, because it reports what has actually been done. Management said the machines have been booked, orders placed with the manufacturers and margins paid, with capital expenditure to be funded mainly from IPO proceeds and working capital possibly met from bankers. That converts the largest execution risk in the earlier research — that the six machinery lines existed only as quotations that would expire — into a delivery and commissioning risk.

The demand side also changed. Our existing research carried an auditor-certified order book of ₹3,034.16 lakhs as at 31 August 2026, roughly 15% of FY26 revenue. On the Q2 FY27 call management put the order book at ₹64.23 crore as on date, alongside second-quarter turnover of ₹32 crore. The later figure is not auditor-certified in the transcript and is not split by product, customer or geography, so it should be treated as a positive, unaudited data point rather than proof of conversion. But a book that has more than doubled in under three months is the strongest single piece of evidence that the demand the company says exceeds its capacity is real at a larger scale than the certified figure showed.

Reported trading, however, was weak. For the half year management reported total revenue of ₹86.08 crore, EBITDA of ₹7.57 crore, PAT of ₹2.58 crore at a 3% margin and EPS of ₹1.68, blaming polymer prices and rainfall. Annualising ₹86.08 crore puts FY27 below the FY26 base unless the second half improves materially. The transcript records EBITDA margin as 'INR8.80 crores', which only reconciles if it means 8.80%; against FY26's 9.69% that is a compression, not an expansion. The pattern is a company adding capacity while its current margin and revenue are running below the recent peak.

The forward programme is where the earnings path sits. The six ordered lines add roughly 6,700 MTPA across PP corrugated sheet, PP honeycomb panel, blow moulded drums, plastic pallets and DWC moulds — new categories rather than extensions of an existing line at scale — targeted at packaging, signage, industrial handling and water infrastructure demand. Phase 1 of the new Athal facility was targeted for operationalisation on or before 31 October 2026 and Phase 2 on or before 31 March 2027. Management now guides trial production two to three months from the November call and commercial production through FY28, with one answer pointing to a first-quarter FY28 start. That is a revision of the production start, not a proved failure of the building, but it means FY27 gets essentially no revenue from the new lines.

Management's stated economic test is a full-capacity revenue potential of ₹135 crore to ₹150 crore, expected to be reached to some extent in FY28-29. This is a target, and a loosely dated one: asked directly, management said it could not predict the outcome now. It also sits below FY26 reported revenue from operations, so whether it is a total, incremental or product-specific figure is unresolved and it should not be treated as a forecast of company revenue. The honest reading is that management is signalling a large step-up in volume from the new lines without committing to a year.

Capital allocation is the more encouraging thread. Funding the machinery from IPO proceeds rather than fresh borrowing keeps incremental interest cost off a balance sheet that already carried cash credit of ₹3,205.77 lakhs at 31 March 2026 and finance cost of ₹604.07 lakhs in FY26, against a proposed IPO debt repayment of only ₹562 lakhs out of ₹4,456.16 lakhs outstanding. The working-capital cycle remains the structural weak point: receivables grew from ₹3,545.53 lakhs in FY24 to ₹5,125.02 lakhs in FY26, with more than six months' outstanding rising from ₹551.10 lakhs to ₹1,201.59 lakhs over the same period. New capacity does not fix that; selling more to the same channels deepens it unless collections improve.

Management delivery on the available record is short. There is one call and no earlier transcript in this bundle, so the only promise that can be checked is the machinery order, which was made within weeks of listing. The commissioning guidance has moved, and the revenue target is undated within a three-year window. That is a mixed record on a thin base, not a proven one either way.

What would confirm the thesis: commercial production starting in the first quarter of FY28 with the ordered lines running, revenue in H2 FY27 improving on H1, and the order book converting into reported revenue rather than growing further. What would falsify it: the new lines commissioning late again into FY29, the order book failing to appear in revenue, or EBITDA margin staying below the FY26 9.69% while receivables and cash credit keep absorbing the incremental sales. The clearest single falsifier is a FY28 without commercial output from the new lines, because then depreciation and fixed cost land against a topline that has already slipped below its FY24 level.

Why is Shree TNB Polymers stock rising?

  • Management put the order book at ₹64.23 crore as on the Q2 FY27 call, against ₹3,034.16 lakhs certified as at 31 August 2026. If those orders execute through existing Silvassa lines, near-term revenue is covered well beyond the earlier 15% of FY26 revenue that the certified figure represented. Second-quarter turnover was stated at ₹32 crore.
  • Management said the company had booked the machines, placed orders for the machine and paid margins to the manufacturers, after the RHP stated that no machinery order had been placed. That converts the main execution risk from vendor re-quotation into delivery, installation and commissioning.
  • Management said capital expenditure will be funded mainly through IPO proceeds received at the 8 October 2026 listing, with bankers to be approached for working capital. Funding the new lines from equity rather than debt keeps incremental interest cost off a business already carrying material cash credit.
  • Management guided trial production within two to three months of the 19 November 2026 call and commercial production running through FY28, describing the year as robust because all machines will be installed. A first-quarter FY28 start would give the new lines their first full twelve months of output in FY28.
  • The ordered lines add PP corrugated sheet, PP honeycomb panel, blow moulded drums and plastic pallets, categories the company did not make at scale. These extend the existing sheets and piping verticals rather than entering unrelated businesses, and management said market teams had already begun contacting customers for the new products.

Research report

companyname: Shree TNB Polymers Limited ticker: SHREETNB sector: Plastics / Polymer Pipes, Fittings & Sheets documenttype: IPO Research Report The issue was a 100% fresh issue of up to 60 lakh equity shares of ₹10 each, with no offer for sale and no selling shareholders, so all money raised less issue expenses went to the company. The issue completed and the company listed on 8 October 2026. On the Q2 FY27 call management said IPO proceeds had been received, that capital expenditure will be fun...

Read the full report →

Growth guidance

Management stated a revenue potential of ₹135 crore to ₹150 crore at full capacity utilisation, expected to be reached to some extent in FY28-29. It guided trial production within two to three months of the 19 November 2026 call and commercial production through FY28, describing FY27-28 as a robust year once all machines are installed, and said capex will be funded mainly through IPO proceeds with working capital possibly from bankers.

Get valuation models, detailed research reports, thematic primers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Shree TNB Polymers and 4,900+ companies.

Sign in
5-day free pass. No card required.